NCT01295320View on ClinicalTrials.gov

Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

June 20, 2013

Study Completion Date

June 20, 2013

Conditions
Herpes Zoster
Interventions
PROCEDURE

Blood sample

Blood sample will be collected at Month 48, Month 60 and Month 72

Trial Locations (11)

13347

GSK Investigational Site, Berlin

30625

GSK Investigational Site, Hanover

45359

GSK Investigational Site, Essen

51069

GSK Investigational Site, Cologne

68161

GSK Investigational Site, Mannheim

97070

GSK Investigational Site, Würzburg

500 01

GSK Investigational Site, Hradec Králové

1018 WT

GSK Investigational Site, Amsterdam

3011 EN

GSK Investigational Site, Rotterdam

SE-631 88

GSK Investigational Site, Eskilstuna

SE-751 85

GSK Investigational Site, Uppsala

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01295320 - Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects | Biotech Hunter | Biotech Hunter